Eli Lillys retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, remains in Phase 3 TRIUMPH trials as of mid-2026, with NDA submission projected no earlier than Q4 2026
More importantly, a large-scale 3b-phase randomized controlled trial (SURMOUNT-5), which compared semaglutide with tirzepatide in 751 obese adults without type 2 diabetes, explicitly reported that male patients had an average weight loss approximately 6 percentage points lower than female patients after 72 weeks of semaglutide treatment, further verifying that sex is an independent factor affecting semaglutides efficacy [80]
OR 3.44), HAQ, and PASI outcomes with concurrent tirzepatide and biologic initiation, alongside markedly lower CRP (4.2 vs 7.7 mg/L
Placebo-controlled cross-over trial in patients with T2DM and albuminuria that shows that liraglutide therapy reduces 24-h urinary albumin excretion by lowering blood pressure, rather than by improving HbA 1c levels and body weight
Interestingly, the more in-depth study found that among high-income households, the drop in grocery spending increased to 8%
